Fas-mediated apoptosis in tumor formation and defense

Biological Chemistry

Volumn 378, Issue 12, 1997, Pages 1405-1412

  Hug, Hubert ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Cancer; Cytostatic drugs; Fas (CD95 APO 1) system; Immune privilege; Programmed cell death; T lymphocytes

Indexed keywords

CELL RECEPTOR; CYTOSTATIC AGENT; DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; METHOTREXATE;

ANTIGEN EXPRESSION; APOPTOSIS; CARCINOGENESIS; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; TUMOR CELL;

EID: 0031454081     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Abbas, A.K. (1996). Die and let live: eliminating dangerous lymphocytes. Cell 84, 655-657.
2. Adachi, M., Suematsu, s., Kondo, T., Ogasawara, J., Tanaka, M., Yoshida, N., and Nagata, S. (1995). Targeted mutation in the Fas gene causes hyperlasia in peripheral lymphoid organs and liver. Nat. Genet. 11, 294-300.
3. Allison, J., Georgiou, H.M., Strasser, A., and Vaux, D.L. (1997). Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94, 3943-3947.
4. Alnemri, E.S., Livingston, D.L., Nicholson, D.W., Salvesen, G., Thornberry, N.A., Wong, W.W., and Yuan, J. (1996). Human ICE/Ced-3 protease nomenclature. Cell 87, 171.
5. Baldini, N. (1997). Multidrug resistance - a multiplex phenomenon. Nat. Med. 3, 378-380.
6. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., and Duke, R.C. (1995). A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632.
7. Berke, G. (1995). The CTL's kiss of death. Cell 81, 9-12.
8. Bodmer, J.L., Burns, K., Schneider, P., Hofmann, K., Steiner, V., Thome, M., Bornand, T., Hahne, M., Schroeter, M., Becker, K., Wilson, A., French, L.E., Browning, J.L., and MacDonald, H.R. (1997). TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor I and Fas (Apo-1/CD95). Immunity 6, 79-88.
9. Boldin, M.P., Goncharov, T.M., Goltsev, Y.V., and Wallach, D. (1996). Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/Apo-1-and TNF receptor-induced cell death. Cell 85, 803-815.
10. Boldin, M.P., Varfolomeev, E.E., Pancer, Z., Mett, I.L., Camonis, J.H., and Wallach, D. (1995). A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270, 7795-7798.
11. Boon, T., Coulie, P.G., and Van den Eynde, B. (1997). Tumor antigens recognized by T cells. Immunol. Today 18, 267-268.
12. Brojatsch, J., Naughton, J., Rolls, M.M., Ziegler, K., and Young, J.A.T. (1996). CAR1, aT NFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis. Cell 87, 845-855.
13. Brunner, T., Mogli, R.J., LaFace, D., Yoo, N.J., Mahboubi, A., Echeverri, F., Martin, S.J., Force, W.R., Lynch, D.H., Ware, C.F., and Green, D.R. (1995). Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441-444.
14. Cheng, J., Zhou, T., Liu, C., Shapiro, J.P., Brauer, M.J., Kiefer, M.C., Barr, P.J., and Mountz, J.D. (1994). Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263, 1759-1762.
15. Chinnaiyan, A.M., O'Rourke, K., Tewari, M., and Dixit, V.M. (1995). FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81, 505-512.
16. Chinnaiyan, A.M., Tepper, C.G., Seldin, M.F., O'Rourke, K., Kischkel, F., Hellbardt, S., Krammer, P.H., Peter, M., and Dixit, V.M. (1996a). FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J. Biol. Chem. 271, 4961-4965.
17. Chinnaiyan, A.M., O'Rourke, K., Yu, G.-L., Lyons, R.H., Garg, M., Duan, R., Xing, L., Gentz, R., Ni, J., and Dixit, V.M. (1996b). Signal tranduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274, 990-992.
18. Chinnaiyan, A.M., and Dixit, V.M. (1997). Portrait of an executioner: the molecular mechanism of Fas/APO-1-induced apoptosis. Sem. Immunol. 9, 69-76.
19. Coney, L.R., Daniel, P.T., Sanborn, D., Dhein, J., Debatin, K.-M., Krammer, P.H., and Zurawski, V.R. (1994). Apoptotic cell death induced by a mouse-human anti-APO-1 chimeric antibody leads to tumor regression. Int. J. Cancer 58, 562-567.
20. Crispe, I.N. (1994). Fatal interactions: Fas-induced apoptosis of mature T cells. Immunity 1, 347-349.
21. Dhein, J., Walczak, H., Bäumler, C., Debatin, K.-M., and Krammer, P.H. (1995). Autocrine T cell suicide mediated by APO-1 (Fas/CD95). Nature 373, 438-441.
22. Eischen, C.M., Kottke, T.J., Martins, L.M., Basi, G.S., Tung, J.S., Earnshaw, W.C., Leibson, P.J., and Kaufmann, S.H. (1997). Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/ Fas ligand interactions. Blood 90, 935-943.
23. Enari, M., Hug, H., and Nagata, S. (1995). Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375, 78-81.
24. Enari, M., Talanian, R.V., Wong, W.W., and Nagata, S. (1996). Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380, 723-726.
25. Fraser, A., and Evan, G. (1996). A license to kill. Cell 85, 781-784.
26. French, L.E., and Tschopp, J. (1997). Thyroiditisand hepatitis: Fas on the road to disease. Nat. Med. 3, 387-388.
27. French, L.E., Hahne, M., Viard, I., Radlgruber, G., Zanone, R., Becker, K., Müller, C., and Tschopp, J. (1996). Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133, 335-343.
28. Friesen, C., Herr, I., Krammer, P.H., and Debatin, K.-M. (1996). Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2, 574-577.
29. Galle, P.R., Hofmann, W.J., Walczak, H., Schaller, H., Otto, G., Stremmel, W., Kramer, P.H., and Runkel, L. (1995). Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182, 1223-1230.
30. Golstein, P., Marguet, D., and Depraetere, V. (1995). Homology between reaper and the cell death domain of Fas and TNFR1. Cell 81, 185-186.
31. Green, D.R., and Ware, C.F. (1997). Fas-ligand: privilege and peril. Proc. Natl. Acad. Sci. USA 94, 5986-5990.
32. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R., and Ferguson, T.A. (1995). Fas ligand induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192.
33. Griffith, T.S., Yu, X., Herndon, J.M., Green, D.R., and Ferguson, T.A. (1996). CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5, 7-16.
34. Hahne, M., Rimoldi, D., Schröter M., Romero, P., Schreier, M., French, L.E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J.-C., and Tschopp, J. (1996). Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366.
35. Hale, A.J., Smith, C.A., Sutherland, L.C., Stoneman, V.E.A., Longthorne, V.L. Culhane, A.C., and Williams, G.T. (1996). Apoptosis: molecular regulation of cell death. Eur. J. Biochem. 236, 1-26.
36. Henkart, P.A. (1994). Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1, 343-346.
37. Hug, H., Enari, M., and Nagata, S. (1994). No requirement of reactive oxygen intermediates in Fas-mediated apoptosis. FEBS Lett. 351, 311-313.
38. Hug, H., Strand, S., Grambihler, A., Galle, J., Hack, V., Stremmel, W., Krammer, P.H., and Galle, P.R. (1997). Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J. Biol. Chem., in press.
39. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A., Seto, Y., and Nagata, S. (1991). The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243.
40. Itoh, N., and Nagata, S. (1993). A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J. Biol. Chem. 268, 10932-10937.
41. Jacobson, M.D., Weil, M., and Raff, M.C. (1997). Programmed cell death in animal development. Cell 88, 348-354.
42. Ju, S.-T., Panka, D.J., Cui, H., Ettinger, R., El-Khatib, M., Sherr, D.H., Stanger, B.Z., and Marshak-Rothstein, A. (1995). Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373, 444-448.
43. Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., and Golstein, P. (1994). Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265, 528-530.
44. Kang, S.-M., Schneider, D.B., Lin, Z., Hanahan, D., Dicher, D.A., Stock, P.G., and Baekkesov, S. (1997). Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3, 738-743.
45. Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K., and Yagita, H. (1995). Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182, 1777-1783.
46. Kayagaki, N., Yamaguchi, N., Nagao, F., Matsuo, S., Maeda, H., Okumura, K., and Yagity, H. (1997). Polymorphism of murine Fas ligand that affects the biological activity. Proc. Natl. Acad. Sci. USA 94, 3914-3919.
47. Kerr, J.F.R., Wyllie, A.H., and Currie, A.R. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239-257.
48. Kischkel, F.C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P.H., and Peter, M.E. (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579-5588.
49. Kitson, J., Raven, T., Jiang, Y.-P., Goeddel, D.V., Giles, K.M., P., K.-T., Grinham, C.J., Brown, R., and Farrow, S.N. (1996). A death-domain-containing receptor that mediates apoptosis. Nature 384, 372-375.
50. Kondo, T., Suda, T., Fukuyama, H., Adachi, M., and Nagata, S. (1997). Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3, 409-413.
51. Lacronique, V., Mignon, A., Fabre, M., Violett, B., Rouquet, N., Molina, T., Porteu, A., Henrion, A., Bouscary, D., Varlet, P., Joulin, V., and Kahn, A. (1996). Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med. 2, 80-86.
52. Lau, H.T., and Stoeckert, C.J. (1997). FasL-too much of a good thing? Nat. Med. 3, 727-728.
53. Lau, H.T., Yu, M., Fontana, A., and Stoeckert Jr., C.J. (1996). Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109-112.
54. Levine, A.J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
55. Los, M., van de Craen, M., Penning, L.C., Schenk, H., Westendorp, M., Baeuerle, P.A., Dröge, W., Krammer, P.H., Fiers, W., and Schulze-Osthoff, K. (1995). Requirement of an ICE/Ced-3 protease for Fas/APO-1-mediated apoptosis. Nature 375, 81-83.
56. Lowin, B., Hahne, M., Mattmann, C., and Tschopp, J. (1994). Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370, 650-652.
57. Marsters, S.A., Sheridan, J.P., Donahue, C.J., Pitti, R.M., Gray, C.L., Goddard, A.D., Bauer, K.D., and Ashkenazi, A. (1996). Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr. Biol. 6, 1669-1676.
58. Mariani, S.M., Matiba, B., Bäumler, C., and Krammer, P.H. (1995). Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 25, 2303-2307.
59. Matiba, B., Mariani, S.M., and Krammer, P.H. (1997). The CD95 system and the death of a lymphocyte. Sem. Immunol. 9, 59-68.
60. Medema, J.P., Scaffidi, C., Kischkel, F.C., Shevchenko, A., Mann, M., Krammer, P.H., and Peter, M.E. (1997). FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16, 2794-2804.
61. Midis, G.P., Shen, Y., and Owen-Schaub, L.B. (1996). Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer. Res. 56, 3870-3874.
62. Miller, D.K. (1997). The role of the caspase family of cystein proteases in apoptosis. Sem. Immunol. 9, 35-49.
63. Müller, M., Strand, S., Hug, H., Heinemann, E.-A., Walczak, H., Hofmann, W.J., Stremmel, W., Krammer, P.H., and Galle, P. (1997). Drug-induced apoptosis in hepatoma cells involves activation of p53 and is mediated by the CD95 (APO1/Fas) receptor/ligand system. J. Clin. Invest. 99, 403-413.
64. Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O'Rourke, K., Shevchonko, A., Ni, J., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Krammer, P.H., Peter, M.E., and Dixit, V.M. (1996). FLICE, a novel FADD-homologous ICE/Ced-3-like protease, is required to the CD95 (Fas/Apo-1) death-inducing signaling complex. Cell 85, 817-827.
65. Nagata, S. (1994). Fas and Fas ligand: a death factor and its receptor. Adv. Immunol. 57, 129-144.
66. Nagata, S. (1996). Fas ligand and immune evasion. Nat. Med. 2, 1306-1307.
67. Nagata, S. (1997). Apoptosis by death factor. Cell 88, 355-365.
68. Nagata, S., and Golstein, P. (1995). The Fas death factor. Science 267, 1449-1456.
69. O'Connell, J., O'Sullivan, G.C., Collins, J.K., and Shanahan, F. (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075-1082.
70. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B.C., Ponstingl, H., and Krammer, P.H. (1992). Purification and molecular cloning of the APO-1 surface antigen, a member of the TNF/NGF receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 267, 10709-10715.
71. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y. Itoh, N., Suda, T., and Nagata, S. (1993). Lethal effect of the anti-Fas antibody in mice. Nature 364, 806-809.
72. Owen-Schaub, L.B., Zhang, W., Cusack, J.C., Angelo, L.S., Santee, S.M., Fujiwara, T., Roth, J.A., Deisserroth, A.B., Zhang, W.-W., Kruzel, E., and Radinsky, R. (1995). Wild-type p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol. 15, 3032-3040.
73. Pan, G., O'Rourke, K., Chinnaiyan, A.M., Gentz, R., Ebner, R., Ni, J., and Dixit, V.M. (1997). The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113.
74. Peter, M.E., Kischkel, F.C., Hellbardt, S., Chinnaiyan, A.M., Krammer, P.H., and Dixit, V.M. (1996). CD95 (APO-1/Fas)-associating signalling proteins. Cell Death Diff. 3, 161-170.
75. Rensing-Ehl, A., Frei, K., Flury, R., Matiba, B., Mariani, S.M., Weller, M., Aebischer, P., Krammer, P.H., and Fontana, A. (1995). Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25, 2253-2258.
76. Rodriguez, I., Matsuura, K., Khatib, K., Reed, J.C., Nagata, S., and Vasalli, P. (1996). A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J. Exp. Med. 183, 1031-1036.
77. Saas, P., Walker, P.R., Hahne, M., Quiquerez, A.-L., Schnuriger, V., Perrin, G., French, L., Van Meir, E.G., deTribolet, N., Tschopp, J., and Dietrich, P.-Y. (1997). Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99, 1173-1178.
78. Schulze-Osthoff, K., Krammer, P.H., and Droge, W. (1994). Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J. 13, 4587-4596.
79. Seino, K.-I., Kayagaki, N., Okumura, K., and Yagita, H. (1997). Antitumor effect of locally produced CD95 ligand. Nat. Med. 3, 165-170.
80. Shimizu, M., Yoshimoto, T., Nagata, S., and Matsuzawa, A. (1996). A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo. Biochem. Biophys. Res. Commun. 228, 375-379.
81. Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K.J., and Takahashi, H. (1997). Expression of Fas ligand in liver metastses of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA 94, 6420-6425.
82. Smith, C.A., Farrah, T., and Goodwin, R.G. (1994). The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76, 959-962.
83. Stanger, B.Z., Leder, P., Lee, T., Kijm, E., and Seed, B. (1995). RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81, 513-523.
84. Strasser, A. (1995). Death of a T cell. Nature 373, 385-386.
85. Strasser, A., Harris, A.W., Huang, D.C.S., Krammer, P.H., and Cory, S. (1995). Bcl-2 and Fas/Apo-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 14, 6136-6147.
86. Strand, S., Hofmann, W.J., Hug, H., Müller, M., Otto, G., Strand, D., Mariani, S.M., Stremmel, W., Kramer, PH., and Galle, P.R. (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2, 1361-1366.
87. Streilein, J.W. (1995). Unraveling immune privilege. Science 270, 1158-1159.
88. Suda, T., Takahashi, T., Golstein, P., and Nagata, S. (1993). Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169-1178.
89. Suda, T., Okazaki, T., Naito, Y., Yokota, N., Arai, S., Ozaki, K., Nakao, K., and Nagata, S. (1995). Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 154, 3806-3813.
90. Tanaka, M., Suda, T., Takahashi, T., and Nagata, S. (1995). Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14, 1129-1135.
91. Tanaka, M., Suda, T., Haze, K., Nakamura, N., Sato, K., Kimura, F., Motoyoshi, K., Mizuki, M., Tagawa, S., Ohga, S., Hatake, K., Drummond, A.H., and Nagata, S. (1996). Fas ligand in human serum. Nat. Med. 2, 317-322.
92. Tartaglia, L.A., Ayres, T.M., Wong, G.H., and Goeddel, D.V. (1993). A novel domain within the 55 kd TNF receptor signals cell death. Cell 74, 845-853.
93. Tewari, M., and Dixit, V.M. (1995). Fas-and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem. 270, 3255-3260.
94. Walker, P.R., Saas, P., and Dietrich, P.-Y. (1997). Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol. 158, 4521-4524.
95. Wakahara, Y., Nawa, A., Okamoto, T., Hayakawa, A., Kikkawa, F., Suganama, N., Wakahara, F., and Tomada, Y. (1997). Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro. Oncogene 54, 48-54.
96. Watanabe-Fukunaga, R., Brannan, C.I., Itoh, N., Yonehara, S., Copeland, N.G., Jenkins, N.A., and Nagata, S. (1992). The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148, 1274-1279.
97. Weller, M., Malipiero, U., Rensing-Ehl, A., Barr, P.J., and Fontana, A. (1995). Fas/APO-1 gene transfer to human malignant glioma. Cancer Res. 55, 2936-2944.
98. White, E. (1996). Life, death, and the pursuit of apoptosis. Genes and Develop. 10, 1-15.
99. Yagita, H., Seino, K.-I., Kayagaki, N., Okumra, K., Duke, R.C., Franzusoff, A., and Bellgrau, D. (1996). CD95 ligand in graft rejection. Nature 379, 682-683.
100. Zhivotovsky, B., Burgess, D.H., Vanags, D.M., and Orrenius, S. (1997). Involvement of cellular proteolytic machinery in apoptosis. Biochem. Biophys. Res. Commun. 230, 481-488.